Show simple item record

Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement

dc.contributor.authorBekaii-Saab, TS
dc.contributor.authorValle, Juan W
dc.contributor.authorBorad, MJ
dc.contributor.authorMelisi, D
dc.contributor.authorVogel, A
dc.contributor.authorFeliz, L
dc.contributor.authorLihou, CF
dc.contributor.authorZhen, HL
dc.contributor.authorAbou-Alfa, GK
dc.date.accessioned2019-11-19T16:01:09Z
dc.date.available2019-11-19T16:01:09Z
dc.date.issued2019en
dc.identifier.citationBekaii-Saab TS, Valle JW, Borad MJ, Melisi D, Vogel A, F�liz L, et al. Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement. J Clin Oncol. 2019;37(4_suppl):TPS462-TPS.en
dc.identifier.doi10.1200/JCO.2019.37.4_suppl.TPS462en
dc.identifier.urihttp://hdl.handle.net/10541/622479
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1200/JCO.2019.37.4_suppl.TPS462en
dc.titleTrial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangementen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMayo Clinic, Phoenix, AZen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record